ClinicalTrials.gg
RecruitingNCT07544264ALLPOLY-TKAUpdated Jun 23, 2026

Evaluation of 5-year Survival and Clinical Outcomes in Patients Undergoing Total Knee Arthroplasty With a Polyethylene Tibial Component

An interventional study of Total knee arthroplasty in Prosthesis Survival and Arthropathy of Knee, sponsored by Istituto Ortopedico Rizzoli. Recruiting at 1 site in Italy. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Istituto Ortopedico Rizzoli · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
78
Allocation
Not applicable
Ages
50 Years to 85 Years
Sex
All
01

Study summary

Total knee arthroplasty (TKA) is one of the most successful procedures in orthopedic surgery for treating advanced knee osteoarthritis, providing pain relief, functional recovery, and improved quality of life. Advances in implant design and materials have further enhanced joint kinematics and patient satisfaction.

An aging population has increased the number of elderly patients with comorbidities, potentially affecting surgical outcomes and implant longevity. Polyethylene has long been used in knee prostheses; early all-polyethylene tibial components were abandoned due to high wear and failure rates, in favor of metal-backed designs, which became the gold standard.

Recently, highly cross-linked ultra-high-molecular-weight polyethylene (UHMWPE) has renewed interest in all-polyethylene tibial components, although their use remains limited. These implants offer potential advantages, including elimination of locking mechanism failures, reduced backside wear, lower costs, and possibly better load distribution.

Evidence from registries, systematic reviews, and meta-analyses shows that 15-year survival of all-polyethylene tibial components is comparable or even superior to metal-backed designs, with no significant differences in clinical-functional outcomes. Additionally, all-poly components are significantly less expensive.

Given these findings, increasing their use and evaluating outcomes in Italy is warranted. The aim of the present study is to assess implant survival of the Link Symphoknee prosthesis with an all-polyethylene tibial component, along with clinical-functional outcomes and post-discharge readmission rates in patients treated at the Rizzoli Orthopaedic Institute.

02

Conditions studied

  • Prosthesis Survival
  • Arthropathy of Knee

Browse trials for

03

In context

Prosthesis Failure

119 studies on the registry are indexed under Prosthesis Failure; 35 are open to participants now.

This study's planned enrollment of 78 is above the median of 36 across 69 interventional studies indexed under Prosthesis Failure.

Browse Prosthesis Failure studies →

Lead sponsor

Istituto Ortopedico Rizzoli is the lead sponsor of 304 studies on the registry; 103 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects aged ≥50 and ≤85 years who are candidates for primary cemented total knee arthroplasty based on physical examination and medical history, including a diagnosis of severe knee pain and disability due to at least one of the following conditions:

    1. Primary or secondary osteoarthritis
    2. Collagen disorders and/or avascular necrosis of the femoral condyle
    3. Moderate valgus, varus, or flexion deformities (Hip-Knee-Ankle angle within ±15°).
  2. Patients who provide consent and are able to complete the scheduled study procedures and follow-up assessments.
  3. Patients who sign the approved by the Ethics Committee.

Exclusion criteria

Exclusion Criteria:

  1. Patients under 50 years of age and over 85 years of age;
  2. Diagnosis of rheumatoid arthritis;
  3. Patients with a contralateral joint prosthesis on the same side;
  4. Coronal plane deformity with a Hip-Knee-Ankle (HKA) angle greater than 15 degrees in varus or valgus.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    TKA

    Implantation of the Link Symphoknee prosthesis with an all-polyethylene tibial component.

    Device: Total knee arthroplasty

Interventions

  • DeviceTotal knee arthroplasty

    Implantation of the Link Symphoknee prosthesis with an all-polyethylene tibial component

06

What researchers measure

Primary outcomes

  1. Implant failure

    It is defined as revision of the prosthesis for any reason-septic, aseptic, or traumatic.

    Time frame: Up to 5 years post-surgery

Secondary outcomes

  1. Knee injury and Osteoarthritis Outcome Score (KOOS)

    It is a subjective score consisting of 42 questions divided into 5 main domains. These domains assess different aspects of symptoms and daily activities, as well as knee-related quality of life.

    Time frame: Up to 5 years post-surgery

  2. Forgotten Joint Score (FJS)

    The Forgotten Joint Score (FJS-12) is a patient-reported outcome measure consisting of 12 questions that assesses how frequently a patient forgets they have a joint prosthesis during daily activities. It measures the patient's perception of the artificial joint rather than pain or function alone, with higher scores (0-100) indicating better "forgetting" of the joint

    Time frame: Up to 5 years post-surgery

  3. Visual Analog Scale (VAS) pain

    A 10-point unidimensional visual analog scale (VAS) for pain assessment, consisting of a 10 cm horizontal line ranging from "no pain" (0) to "worst imaginable pain" (10). The patient marks their perceived pain intensity on the line, and the distance from zero is measured to quantify pain. It is also used pre- and post-operatively to assess lateral knee pain; a score \>2 is considered the presence of lateral compartment pain, while ≤2 indicates its absence

    Time frame: Up to 5 years post-surgery

  4. VAS Satisfaction

    Intraoperative and postoperative complications will be recorded. Any hospital readmissions within 90 days of discharge after the arthroplasty procedure will also be documented

    Time frame: Up to 5 years post-surgery

  5. Hip-Knee-Ankle angle (HKA)

    It is the angle that measures the mechanical alignment of the lower limb, drawn between the hip, knee, and ankle axes on a weight-bearing radiograph. It is used to assess whether the leg is neutrally aligned or shows varus or valgus deformity

    Time frame: Up to 5 years post-surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Oct 2032, 77 months after the start.

Of 48 non-industry interventional studies with no phase under Prosthesis Failure, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 77 months is above that.

Counting every sponsor, half of 50 studies reached it within 18 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2026
First posted
Apr 22, 2026
StartActual
May 13, 2026
Primary completionEst.
Oct 2032
CompletionEst.
Oct 2032
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07544264
Responsible party
Stefano Zaffagnini (Full Professor Medicine and Surgery, University of Bologna, Istituto Ortopedico Rizzoli) — Principal investigator
First posted
Apr 22, 2026
Start date
May 13, 2026
Primary completion
Oct 2032 (estimated)
Completion
Oct 2032 (estimated)
Last update
Jun 23, 2026

Study contacts

stefano zaffagnini
Contact
stefano.zaffagnini@unibo.it
0516366075

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion